NEW YORK, Dec. 11, 2024 /PRNewswire/ -- A2A Pharmaceuticals, Inc. ("A2A or "the company"), a clinical-stage pioneering biopharmaceutical company focused

LOS ANGELES, Dec. 11, 2024 /PRNewswire/ -- Fitness entrepreneur and philanthropist Anthony Geisler provided a generous donation this holiday season

Closing marks second significant acquisition from RA Capital's Raven incubator in 2024, and first acquisition of a company built by

NEW YORK, Dec. 11, 2024 /PRNewswire/ -- Report on how AI is redefining market landscape - The global heparin market

T-cell malignancies account for about 10-15% of all lymphoid malignancies, and their treatment often involves chemotherapy, immunotherapy, or stem cell